114 related articles for article (PubMed ID: 28665782)
1. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.
Kaneko MK; Kunita A; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Ogasawara S; Ohishi T; Abe S; Itai S; Harada H; Kawada M; Nishioka Y; Fukayama M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):157-162. PubMed ID: 28665782
[TBL] [Abstract][Full Text] [Related]
2. PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.
Ogasawara S; Kaneko MK; Yamada S; Honma R; Nakamura T; Saidoh N; Yanaka M; Yoshida K; Fujii Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):50-56. PubMed ID: 28384052
[TBL] [Abstract][Full Text] [Related]
3. A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.
Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203331
[TBL] [Abstract][Full Text] [Related]
4. A cancer-specific anti-podocalyxin monoclonal antibody (60-mG
Kaneko MK; Ohishi T; Kawada M; Kato Y
Biochem Biophys Rep; 2020 Dec; 24():100826. PubMed ID: 33088928
[TBL] [Abstract][Full Text] [Related]
5. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
Itai S; Ohishi T; Kaneko MK; Yamada S; Abe S; Nakamura T; Yanaka M; Chang YW; Ohba SI; Nishioka Y; Kawada M; Harada H; Kato Y
Oncotarget; 2018 Apr; 9(32):22480-22497. PubMed ID: 29854293
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Analysis Using Antipodocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinomas.
Itai S; Yamada S; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):220-223. PubMed ID: 28873000
[TBL] [Abstract][Full Text] [Related]
7. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
8. 47-mG
Kaneko MK; Itai S; Yamada S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Jun; 37(3):158-161. PubMed ID: 29630446
[TBL] [Abstract][Full Text] [Related]
9. Epitope Mapping of a Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (PcMab-60) Using Enzyme-Linked Immunosorbent Assay and Surface Plasmon Resonance.
Asano T; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Oct; 40(5):227-232. PubMed ID: 34678093
[TBL] [Abstract][Full Text] [Related]
10. Anti-Podocalyxin Monoclonal Antibody 47-mG
Yamada S; Itai S; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):91-94. PubMed ID: 29649375
[TBL] [Abstract][Full Text] [Related]
11. PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.
Canals Hernaez D; Hughes MR; Dean P; Bergqvist P; Samudio I; Blixt O; Wiedemeyer K; Li Y; Bond C; Cruz E; Köbel M; Gilks B; Roskelley CD; McNagny KM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243933
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
13. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy.
Snyder KA; Hughes MR; Hedberg B; Brandon J; Hernaez DC; Bergqvist P; Cruz F; Po K; Graves ML; Turvey ME; Nielsen JS; Wilkins JA; McColl SR; Babcook JS; Roskelley CD; McNagny KM
Breast Cancer Res; 2015 Mar; 17(1):46. PubMed ID: 25887862
[TBL] [Abstract][Full Text] [Related]
14. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
[TBL] [Abstract][Full Text] [Related]
15. An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H
Kato Y; Ohishi T; Takei J; Nakamura T; Kawada M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Aug; 39(4):135-139. PubMed ID: 32644843
[TBL] [Abstract][Full Text] [Related]
16. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
[TBL] [Abstract][Full Text] [Related]
17. Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.
Funahashi SI; Kawai S; Fujii E; Taniguchi K; Nakano K; Ishikawa S; Aburatani H; Suzuki M
J Biochem; 2018 Dec; 164(6):471-481. PubMed ID: 30239818
[TBL] [Abstract][Full Text] [Related]
18. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract][Full Text] [Related]
19. Determination of critical epitope of PcMab-47 against human podocalyxin.
Itai S; Yamada S; Kaneko MK; Kato Y
Biochem Biophys Rep; 2018 Jul; 14():78-82. PubMed ID: 29872738
[TBL] [Abstract][Full Text] [Related]
20. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
